United Services Automobile Association acquired a new position in shares of Myriad Genetics, Inc. (NASDAQ:MYGN) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 25,670 shares of the company’s stock, valued at approximately $493,000.
Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. Highbridge Capital Management LLC boosted its stake in shares of Myriad Genetics by 6.4% in the fourth quarter. Highbridge Capital Management LLC now owns 28,196 shares of the company’s stock valued at $470,000 after buying an additional 1,704 shares in the last quarter. Opus Point Partners Management LLC purchased a new stake in shares of Myriad Genetics during the fourth quarter valued at $232,000. Teachers Advisors LLC boosted its stake in shares of Myriad Genetics by 4.6% in the fourth quarter. Teachers Advisors LLC now owns 115,637 shares of the company’s stock valued at $1,928,000 after buying an additional 5,051 shares in the last quarter. Camber Capital Management LLC purchased a new stake in shares of Myriad Genetics during the fourth quarter valued at $67,680,000. Finally, Norges Bank purchased a new stake in shares of Myriad Genetics during the fourth quarter valued at $14,319,000.
Shares of Myriad Genetics, Inc. (MYGN) traded up 0.85% during mid-day trading on Friday, hitting $23.66. 613,248 shares of the company traded hands. The firm has a 50-day moving average of $24.67 and a 200-day moving average of $20.23. The stock has a market capitalization of $1.61 billion, a price-to-earnings ratio of 50.56 and a beta of 0.32. Myriad Genetics, Inc. has a one year low of $15.15 and a one year high of $32.05.
Myriad Genetics (NASDAQ:MYGN) last issued its earnings results on Tuesday, May 2nd. The company reported $0.27 earnings per share for the quarter, topping analysts’ consensus estimates of $0.24 by $0.03. The firm had revenue of $196.90 million during the quarter, compared to analyst estimates of $188.89 million. Myriad Genetics had a net margin of 4.26% and a return on equity of 10.53%. On average, equities analysts predict that Myriad Genetics, Inc. will post $1.01 earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: “United Services Automobile Association Buys Shares of 25,670 Myriad Genetics, Inc. (MYGN)” was reported by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international copyright law. The original version of this news story can be accessed at https://sportsperspectives.com/2017/07/28/united-services-automobile-association-invests-493000-in-myriad-genetics-inc-mygn-updated-updated-updated.html.
Several analysts have weighed in on MYGN shares. BidaskClub raised shares of Myriad Genetics from a “hold” rating to a “buy” rating in a research note on Saturday, June 17th. Jefferies Group LLC reissued a “hold” rating and set a $21.00 price target (up from $18.00) on shares of Myriad Genetics in a research note on Wednesday, May 3rd. Cowen and Company reaffirmed a “hold” rating and issued a $25.00 price objective on shares of Myriad Genetics in a research note on Friday, July 14th. Deutsche Bank AG raised their price objective on shares of Myriad Genetics from $15.00 to $20.00 and gave the company a “sell” rating in a research note on Monday, May 8th. Finally, J P Morgan Chase & Co reaffirmed an “underweight” rating and issued a $16.00 price objective on shares of Myriad Genetics in a research note on Friday, June 30th. Five investment analysts have rated the stock with a sell rating, eight have given a hold rating and three have assigned a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $22.00.
About Myriad Genetics
Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.
Receive News & Ratings for Myriad Genetics Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Myriad Genetics Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.